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Background: The Provisional Diagnostic Instrument (PDI-4) is a brief, adult self-report instrument for 4 common
psychiatric diagnoses in primary care patients: major depressive episode (MDE), generalized anxiety disorder (GAD),
attention deficit hyperactivity disorder (ADHD), and bipolar I disorder based on past or present mania. Our objective
was to assess validity of the PDI-4 in a population independent of the study population originally used to develop
the scale.
Methods: An online version of the 17-item PDI-4 was administered to 1,047 adults in the US; respondents also
completed the PHQ-9, HADS-A, CAARS-S, and MDQ within the online survey. Respondents self-reported diagnosis
by a healthcare professional with the terms depression (n=221), anxiety (n=218), attention deficit disorder (n=206),
bipolar or manic depressive disorder (n=195), or none of these (n=207). Statistical analyses examined convergent
and discriminant validity, and operating characteristics of the PDI-4 relative to the individual, validated, self-rated
scales PHQ-9, HADS-A, CAARS-S, and MDQ, for each PDI-4 diagnosis.
Results: Convergent validity of the PDI-4 was supported by strong correlations with the corresponding individual
scales (range of 0.63 [PDI-4 and MDQ] to 0.87 [PDI-4 and PHQ-9]). Operating characteristics of the PDI-4 were similar
to results in the previous site-based study. The scale exhibited moderate sensitivities (0.52 [mania] to 0.70 [ADHD])
and strong specificities (0.86 [mania] to 0.92 [GAD]) using the individual scales as the gold standards. ANOVAs
demonstrated that PDI-4 discriminated between subsets of patients defined by pre-specified severity level cutoff
scores of the individual scales. However, overlapping symptoms and co-morbidities made differentiation between
mental diagnoses much weaker than differentiation from the control group with none of the diagnoses.
Conclusions: The PDI-4 appears to be a suitable, brief, self-rated tool for provisional diagnoses of common mental
disorders. However, the high level of symptom overlap between these diagnoses emphasizes that such brief scales
are not a replacement for thorough diagnostic evaluation by trained medical providers.
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The need for accurate diagnoses is great due to the rate
of mental disorders in the general population and the
consequences of undiagnosed or incorrect diagnoses.
Previous estimates have suggested 20% of primary care
patients have a mental disorder, and these often go
undetected [1] resulting in reductions in quality of life,
increased healthcare costs, decreased productivity, and
greater functional impairment [2-6]. The prevalence
rates of the PDI-4 diagnoses in primary care populations* Correspondence: faries_douglas_e@lilly.com
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reproduction in any medium, provided the orare quite high: 8% to 15% for adult attention deficit
hyperactivity disorder (ADHD) [7,8], 10% for bipolar
spectrum disorders [9], 4% to 19% for major depressive
episode (MDE) [10,11], and 7% to 15% for generalized
anxiety disorder (GAD) [10,12].
The PDI-4 (Additional file 1)is a patient-completed,
diagnostic tool developed to assist in the determination
of the following 4 psychiatric diagnoses often encoun-
tered in primary care settings: MDE, GAD, ADHD, and
bipolar I disorder based on a history of past or present
mania [13]. The scale consists of 17 items: 4 assessing
frequency of specific symptoms from each of the 4 tar-
geted diagnoses, and a final question assessing the impact
on functioning. For consideration of each diagnosis,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the specified cutoff frequency [13]. The tool was created
to assist with the diagnoses of mental disorders in pri-
mary care settings, where time constraints typically limit
the ability to utilize healthcare professional-administered
diagnostic interviews. Screening for mental disorders is
often complicated by overlapping symptoms, co-morbid
diagnoses, and need for extensive training with diagnos-
tic instruments. While several validated patient-rated
scales exist that are used as screening instruments for
specific diagnoses, a single tool is needed to screen for
multiple, common diagnoses due to co-morbidities and
overlapping symptoms.
The initial validation of the PDI-4 was conducted in
an in-person study of 704 patients conducted within pri-
mary care office settings [14]. Based on this study, the
scoring rules for the scale were created, and operating
characteristics of the scale were estimated in relation to
gold standard diagnostic interviews (Structured Clinical
Interview Research Version [SCID] for Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edi-
tion [DSM-IV] axis I disorders and the Adult ADHD
Clinician Diagnostic Scale version 1.2 [ACDS] [15,16]).
Houston et al. observed respective sensitivities and spe-
cificities of 83% and 75% for GAD, 80% and 80% for
MDE, 83% and 82% for mania, and 82% and 73% for
ADHD [14]. Concurrent validity was established by
demonstrating expected correlations with existing vali-
dated scales for the specific diagnoses, and the impact of
elevated scores on the PDI-4 was demonstrated by
impairment measured by the Mental Component Score
and the Physical Component Score on the 12-item Med-
ical Outcomes Study Short-Form Health [17]. Houston
et al. [14] later studied the properties of the PDI-4 for
additional anxiety-related diagnoses. However, cross-
validation of the scale was needed due to the small sam-
ple sizes for select populations. The scoring rules and
operating characteristics were based on the same pri-
mary care-based sample; therefore, the instrument and
its operating characteristics needed to be examined in
an independent sample and in a more diverse patient
population.
In the current study, a cross-sectional survey was
administered to provide additional data to assess the
validation of the PDI-4 and its generalizability to a more
diverse population in a non site-based setting.
Methods
Study design and participants
This study was a cross-sectional survey of 5 cohorts of
adults in the United States (US). Four of the cohorts
were patients selected due to self-report of a previous
diagnosis by a healthcare professional with at least 1 of
the 4 disorders corresponding to the PDI-4: depressionfor MDE, anxiety for GAD, attention deficit disorder for
ADHD, and bipolar or manic depressive disorder for
past/present mania. The fifth cohort was a random sam-
ple of patients that did not self-report any of the 4 diag-
noses. Harris Interactive participated in the design and
administration of the survey in their pre-established
national participant panel.
Participants were at least 18 years old, had at least a
sixth grade education, and were recruited from the
closed-membership Harris Chronic Illness Panel (a sub-
set of the multi-million member Harris Pole Online
Panel). Participants were sampled so that they repre-
sented all major US regions, with a goal of including at
least 20% elderly patients, no more than 65% men or
women, and an adequate minority representation. Poten-
tial participants received an e-mail invitation to a single-
use, password-protected survey site. The overall goal
was to obtain survey data from 1000 participants with
approximately 200 from each cohort. This sample size
was selected because it would provide sufficient power
and sensitivity for each of the planned analyses (ie, pro-
vide planned accuracy for confidence intervals for con-
current validity and provide power for effect-size
differences in known groups validity). The survey
screened respondents for inclusion in the study, and
those who qualified gave consent via a checkmark within
the survey prior to their inclusion in the study. The
Copernicus Group Institutional Review Board approved
the conduct of the study.
Questionnaire
The survey administered to all patients consisted of 78
items and was estimated to take approximately 15 min-
utes to complete. Items included the following: demo-
graphics and other participant characteristics (age,
gender, race, education, income, mental disorder diag-
noses, mental disorder medication use, marital status,
employment status, geographic region, and recent physi-
cian visits); the 17 items from the PDI-4 scale, and items
from comparator-validated, patient-rated scales for each
of the following diagnoses: the Patient Health Question-
naire (PHQ-9) for MDE, the Anxiety subscale of the
Hospital Anxiety and Depression Scale (HADS-A) for
GAD, the Conners’ Adult ADHD Rating Scale Self
Report (CAARS-S) for ADHD, and the Mood Disorder
Questionnaire (MDQ) for mania. These comparator
scales were selected because they are well-studied, vali-
dated, self-report scales that allow comparisons with
previous work; these scales were all used in the initial
study of the PDI-4 [1,14]. The PHQ-9 is a 9-item,
participant-reported scale that parallels the 9 DSM-IV
diagnostic symptoms of depression [18]. The HADS was
originally developed to identify depression and anxiety
symptoms in a non-psychiatric hospital setting and
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scale (HADS-A) used in this study [19]. The CAARS-S
Screening Version assesses symptoms and behaviors
related to adult ADHD [20]. The DSM-IV Symptoms
subscale of the CAARS-S was used in this study. The
MDQ is a 15-item scale assessing past and present
mania [21].
Statistical methods
Descriptive statistics were used to summarize the popu-
lation of subjects completing the survey as well as the
overlap in symptoms across the 4 diagnoses. The analy-
sis of the PDI-4 included assessment of concurrent
validity and known groups validity (discriminant), and a
summary of the operating characteristics of the tool in
this population.
Each symptom item of the PDI-4 was assigned a score
of 0, 1, 2, 3, or 4, depending on symptom frequency
endorsed. Concurrent validity was assessed using corre-
lations among the resulting 4-item score sum for each of
the four PDI-4 subscales and the validated scale for each
diagnosis (PHQ-9, MDQ, CAARS-S, and HADS-A). It
was hypothesized that the PDI-4 subscales would corre-
late strongly with the corresponding validated scale (eg,
PDI-4 MDE with the PHQ-9) and positively but less
strongly with the other subscales and scales, providing
similar results to those seen in the initial validation
study.
The sensitivity, specificity, positive predicted value,
and negative predicted value of each PDI-4 subscale
were computed. As formal diagnostic interviews were
not performed in this study, the corresponding patient
scales with published cutoff scores (PHQ-9 score ≥ 12,
HADS-A score ≥ 14, CAARS-S score ≥ 28, and MDQ
score ≥ 7 with functioning item score of ≥ 3) were
used to establish a “diagnosis” for PDI-4 comparison
for the calculations of sensitivity, specificity, and posi-
tive and negative predicted value calculations. These
cutoff scores were previously used by Houston et al.
[13] in primary care patients and produced the follow-
ing operating characteristics for each scale (sensitivity,
specificity) relative to structured diagnostic interviews:
PHQ-9 for MDE (0.79, 0.81), HADS-A for GAD (0.54,
0.81), CAARS-S for ADHD (0.54, 0.87), and MDQ for
mania (0.83, 0.63).
Known groups (discriminant) validity was summarized
using analysis of variance (ANOVA) models for each of
the four PDI-4 subscales. Each model utilized a PDI-4
subscale as the outcome measure, with terms for cohort
(based on the corresponding diagnosis), gender, age, and
race. It was hypothesized that groups with the diagnosis
would have significantly higher PDI-4 scores than
patients without the corresponding diagnosis, where the
diagnosis cohorts were determined by an independentmeasure. Specifically, cohorts were diagnosed based on
published cutoff scores for the PHQ-9 (score ≥ 12),
HADS-A (score ≥ 14), CAARS-S (score ≥ 28), and MDQ
(score ≥ 7 with functioning item score of ≥ 3). For the
assessment of the PDI-4 depression subscale, the
ANOVA model was utilized to detect differences using
the PDI-4 subscales between cohorts with PHQ-9
depression versus subjects without PHQ-9 depression.
The negative group was then subdivided into partici-
pants with none of the other 3 diagnoses and partici-
pants with at least 1 of the other 3 diagnoses. Similar
models were conducted for the PDI-4 GAD, ADHD, and
mania subscale scores.
Results
The sample size targets were met with 1,047 subjects
completing the online interview in the second half of
2010, and approximately 200 of them were within each
cohort. Table 1 summarizes the characteristics of the
sample population, including scores on the PDI-4 and
corresponding scale. Cohorts for this initial summary
were based on the patients’ self-report of diagnoses given
to them by their physician. The overall sample was
approximately 60% female and 84% Caucasian, with an
average age of 51 years. Figure 1 describes the co-
morbidities and overlapping symptoms in the sample by
defining GAD, MDE, ADHD, and mania using published
cutoff scores from the validated scales (PHQ-9, HADS-
A, CAARS-S, and MDQ). The high prevalence of over-
lapping symptoms is apparent. For instance, among
patients meeting the diagnosis cutoff score for GAD
based on the HADS-A, 89.5% also equaled or exceeded
the diagnostic cutoffs for 1 or more additional condi-
tions (MDE by PHQ-9, ADHD by the CAARS-S, and/or
mania by the MDQ). Indeed, 82% met or exceeded the
PHQ-9 cutpoint for MDE.
Table 2 summarizes concurrent validity by providing
the correlations of the PDI-4 subscales with the corre-
sponding diagnosis rating scales. As hypothesized, each
PDI-4 subscale had higher correlations with the corre-
sponding scale (eg, PDI-4 MDE with PHQ-9) than with
any other scale. Correlations were positive and moderate
to high among all scales (minimum of 0.33 between both
PDI-4 GAD and PDI-4 MDE with the MDQ), which is
consistent with the large amount of overlapping symp-
toms observed between the PHQ-9, HADS-A, CAARS-
S, and MDQ (see Figure 1).
The operating characteristics of the PDI-4 in this
sample are provided in Table 3. Note that the gold
standard in each case was compared to published
cutoff points from the corresponding rating scale
(HADS-A, PHQ-9, CAARS, and MDQ) and not to a
diagnostic interview by a clinician, which was unavail-
able here. Sensitivities and positive predictive values













Gender (% female) 59.6% 59.6% 59.3% 51.0% 66.2% 62.3%
Age, years (SD) 51.4 (16.5) 50.3 (17.7) 51.4 (17.1) 51.5 (14.4) 52.1 (12.1) 51.5 (19.7)
Ethnicity (% Caucasian) 84.1% 88.5% 81.5% 87.3% 89.2% 73.0%
Education (% completed
high school)
98.5% 97.6% 99.5% 98.5% 98.5% 98.5%
Income (mode) $35,000 to $49,000 $35,000 to $49,000 $35,000 to $49,000 $50,000 to $74,000 $35,000 to $49,000 $35,000 to $49,000
PDI-4 GAD, mean (SD) 7.0 (3.6) 8.0 (3.5) 7.2 (3.0) 7.3 (3.4) 8.5 (3.3) 4.2 (3.2)
PDI-4 MDE, mean (SD) 5.9 (3.9) 6.7 (3.8) 6.5 (3.3) 5.8 (3.7) 7.9 (3.9) 2.9 (2.9)
PDI-4 ADHD, mean (SD) 4.9 (3.1) 4.9 (2.9) 4.8 (2.7) 5.8 (2.9) 6.4 (3.2) 2.8 (2.5)
PDI-4 Mania, mean (SD) 5.2 (3.7) 4.7 (3.1) 4.3 (3.1) 6.4 (3.5) 7.9 (3.8) 3.1 (2.9)
Abbreviations: ADHD = attention deficit hyperactivity disorder; GAD = generalized anxiety disorder; MDE = major depressive episode; PDI-4 = Provisional
Diagnostic Instrument; SD = standard deviation.
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to 0.70; positive predictive values, from 0.44 to 0.72).
Specificities and negative predictive values were high,
ranging from 0.86 to 0.92 and 0.86 to 0.96, respec-
tively, indicating the potential value of the PDI-4 to
rule out diagnoses.
Figure 2 summarizes the mean PDI-4 subscale scores
based on cohorts used in the known groups (discrimi-
nant) validity analyses. As hypothesized, each subscale
of the PDI-4 was able to discriminate between groups
based on an independent assessment for each of the
corresponding diagnoses (p<0.05 in all cases). For
instance, PDI-4 GAD scores were statistically signifi-
cantly higher in participants who met the HADS-A
criteria for anxiety than in participants who did not
(p<0.001). Mean subscale score differences between
cohorts with and without the diagnosis were large
in all cases, ranging from 3.3 (mania) to 5.5 (MDE).

































Figure 1 Summary of overlapping symptoms based on PHQ-9, HADS
ADHD = attention deficit hyperactivity disorder; Anx = anxiety; GAD = gen
on the x-axis denote patients meeting the cutoff score for the correspondi
for GAD, CAARS-S score ≥ 28 for ADHD, MDQ score ≥ 7 with functioning i
computing the percentages of patients with other diagnoses denoted insidsignificantly higher in participants who met the
HADS-A criteria for anxiety than in 1) participants
who did not meet the HADS-A criteria but did meet
criteria for 1 of the other diagnoses (PHQ-9 for MDE,
CAARS for ADHD, and MDQ for mania), and 2) par-
ticipants who did not meet HADS-A criteria nor cri-
teria for any of the other diagnoses. When comparing
to patients with co-morbidities (eg, for anxiety, looking
at patients with anxiety versus those without anxiety
but with 1 of the other 3 diagnoses), cohort differences
on the PDI-4 scales were smaller (range 2.0 to 4.8)
but remained statistically significantly different in all
analyses.Discussion
In this cross-sectional cross-validation study, concurrent
validity and known groups validity of the PDI-4 were
examined using an established closed-panel internet42.0%
it Mania








-A, CAARS-S, and MDQ screening cutoff points. Abbreviations:
eralized anxiety disorder; MDD = major depressive disorder. The labels
ng patient-rated scale: PHQ-9 score ≥ 12 for MDE, HADS-A score ≥ 14
tem score of ≥ 3 for mania. The same definitions are used in
e each histogram bar.
Table 2 Correlations between the four PDI-4 scales and
corresponding diagnosis scales (PHQ-9, HADS-A,
CAARS-S, and MDQ)
PDI-4 GAD PDI-4 MDE PDI-4 ADHD PDI-4 Mania
HADS-A 0.76 0.72 0.66 0.52
PHQ-9 0.75 0.87 0.68 0.46
CAARS-S 0.57 0.54 0.75 0.59
MDQ 0.33 0.33 0.46 0.63
Abbreviations: ADHD = attention deficit hyperactivity disorder;
CAARS-S = Conners’ Adult ADHD Rating Scale Self Report; HADS-A = Hospital
Anxiety and Depression Scale-Anxiety subscale; MDE = major depressive
episode; MDQ = Mood Disorder Questionnaire; PDI-4 = Provisional Diagnostic
Instrument; PHQ-9 = Patient Health Questionnaire for depression.
Note: Pearson correlation coefficients are reported. All correlations are
significant, p<0.001.
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the PDI-4 and comparator scales were assessed.
The evidence supporting the concurrent validity of the
scale was strong. Correlations with other validated scales
measuring the same concepts were high, as expected. In
fact, the observed correlations were extremely close to
the correlations observed in the initial site-based study
of the PDI-4. This suggests the scales perform similarly
in this population and with this mode of administration
as seen in the original PDI-4 office site-based paper
approach. Although no confirmation of diagnoses using
the gold standard of trained clinician interviews was
available, relative to validated patient-rated scales, the
observed specificity values were high, sensitivity values
were moderate to high, and negative predicted values
were high. Note that the positive predictive values in this
type of sample – where patients are self-selected to have
greater rates of mental health disorders – would be
expected to be lower in a general population sample
where the prevalence of mental disorders is lower [22].
The study also provided further support for the discri-
minant validity of the PDI-4. Large and statistically sig-
nificant consistencies were observed between the PDI-4
in patients who did and did not meet diagnostic cut-
points for GAD, MDE, ADHD, and mania based
on independent, validated scales for each diagnosis.Table 3 Operating characteristics of PDI-4 based diagnosis re
Operating Characteristics
PDI-4 Scale Comparator Scale
Diagnostic Cutoff
Sensitivity (95% CI) Sp
PDI-4-GAD HADS-A (≥ 14) 0.64 (0.54, 0.74) 0.9
PDI-4-MDE PHQ-9 (≥ 12) 0.69 (0.64, 0.75) 0.9
PDI-4-ADHD CAARS-S (≥ 28) 0.70 (0.62, 0.77) 0.8
PDI-4-Mania MDQ (≥ 7) 0.52 (0.46, 0.59) 0.8
Abbreviations: ADHD = attention deficit hyperactivity disorder; CAARS-S = Conners’
HADS-A = Hospital Anxiety and Depression Scale-Anxiety subscale; GAD = generaliz
Questionnaire; NPV = negative predictive value; PDI-4 = Provisional Diagnostic Instr
predictive value.Comparisons between groups of patients with a given
validated scale-based diagnosis, for example, GAD based
on HADS-A, and those without GAD but with a scale-
based diagnosis of MDE, ADHD, or mania, highlighted
the challenges clinicians face in making specific diag-
noses with overlapping symptoms. Differences in PDI-4
summed subsection severity scores between such patient
cohorts were much smaller, though the PDI-4 scores still
demonstrated statistical separation between patients
with and without a particular diagnosis in all cases.
These results are consistent with overlapping diagnos-
tic symptom criteria for these 4 diagnoses as well as with
partial overlap in pharmacologic treatments indicated
for the treatment of the diagnoses. This underscores the
need for careful clinician analysis which considers the
possibility of multiple diagnoses in the selection of treat-
ments since misdiagnosis and inappropriate treatment is
potentially disastrous; for example, treatment of a major
depressive episode in a bipolar I patient with an antide-
pressant alone could result in a manic episode. The PDI-
4 is a tool designed to assist in diagnosis and to broaden
diagnostic considerations, but it is not a substitute for
clinical assessment.
One major limitation of this study was the lack of gold
standard diagnostic interviews performed by trained
clinicians. This meant that the operating characteristics
(sensitivity, specificity) of the PDI-4 as well as the known
groups validity analyses had to be assessed relative to
other validated self-rating scales rather than the standard
of using diagnostic interviews. It is unclear how the
results may have differed had diagnostic interviews been
performed and cohorts based on these data would have
been available.
Another limitation of this study is the reliance on an
internet sample of participants with self reported diag-
noses. It is known that internet samples will differ to
some unknown degree from a random sample of
patients attending primary care centers. However, inter-
net usage is increasing and thus “online samples” are
becoming more like a general population sample in the
US. Regardless, the PDI-4 validity evidence found in thislative to diagnosis based on corresponding rating scales
of PDI-4 Scale Using the Comparator Scale Diagnostic Cutoff
ecificity (95% CI) PPV (95% CI) NPV (95% CI)
2 (0.90, 0.93) 0.44 (0.35, 0.52) 0.96 (0.95, 0.97)
0 (0.88, 0.92) 0.72 (0.66, 0.77) 0.89 (0.87, 0.91)
7 (0.85, 0.89) 0.49 (0.42, 0.55) 0.94 (0.93, 0.96)
6 (0.83, 0.88) 0.52 (0.46, 0.59) 0.86 (0.83, 0.88)
Adult ADHD Rating Scale Self Report; CI = confidence interval;
ed anxiety disorder; MDE = major depressive episode; MDQ = Mood Disorder
ument; PHQ-9 = Patient Health Questionnaire for depression; PPV = positive
Figure 2 Known groups validity: summary of mean PDI-4 subscale scores in cohorts diagnosed with other rating scales.
Abbreviations: ADHD = attention deficit hyperactivity disorder; CAARS-S = Conners’ Adult ADHD Rating Scale Self Report; Depress = depression;
GAD = generalized anxiety disorder; HADS-A = Hospital Anxiety and Depression Scale-Anxiety subscale; MDE = major depressive episode;
MDQ = Mood Disorder Questionnaire; PDI-4 = Provisional Diagnostic Instrument; PHQ-9 = Patient Health Questionnaire. P-values are from
contrasts among the cohorts (comparing to the left most histogram bar) from the ANOVA model with the corresponding PDI-4 scale as the
dependent variable and the following independent variables in the model: diagnostic cohorts, age, gender, and race. The Diagnostic Cohorts
variable was a categorical grouping of patients into 3 categories: 1) patients meeting the corresponding cutoff score (PHQ-9 score ≥ 12 if PDI-4
MDE is the dependent variable, HADS-A score ≥ 14 if PDI-4 GAD is the dependent variable, CAARS-S score ≥ 28 if PDI-4 ADHD is the dependent
variable, or MDQ score ≥ 7 with functioning item score of ≥ 3 if PDI-4 Mania is the dependent variable); 2) patients not meeting the cutoff
score for the corresponding disease but who do meet at least 1 of the other 3 cutoff scores (denoted by “comorbidity” in the graphs); and
3) patients not meeting the cutoff score for the corresponding disease or any of the other 3 diagnoses.
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national primary care population.
Conclusions
In total, these findings in a new sample and with a new
mode of administration support prior office-based evi-
dence that the PDI-4 appears to be a valid, brief self-
rated instrument for assisting with the assessment of 4
common psychiatric diagnoses. It is important to note
that given the large amount of symptom overlap in these
diagnoses, such brief scales cannot replace thorough
diagnostic evaluation by trained medical caregivers.
However, the data suggest the PDI-4 can be a useful tool
in the overall process of appropriate diagnosis of mental
disorders.Additional file
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